Survey to assess physicians' knowledge of Exjade posology and biological monitoring recommendations as described in the Educational Materials

Study type

• Study type:
  Non-interventional study

Study drug and medical condition

• Name of medicine:
  EXJADE
• Study drug International non-proprietary name (INN) or common name:
  DEFERASIROX
• Anatomical Therapeutic Chemical (ATC) code:
  (V03AC03) deferasirox

  deferasirox

Population studied

• Age groups:
  • Adult and elderly population (≥18 years)

    • Adults (18 to < 65 years)

      • Adults (18 to < 46 years)
      • Adults (46 to < 65 years)
    • Elderly (≥ 65 years)

      • Adults (65 to < 75 years)
      • Adults (75 to < 85 years)
      • Adults (85 years and over)
• Estimated number of subjects:
  400

Study design details

• Main study objective:
  To evaluate the effectiveness of Educational Material for Exjade (deferasirox)
• Outcomes:
  Percentage of correct response rate to the physician survey questionnaire
• Data analysis plan:
  Physician knowledge will be evaluated in each of the two key sections separately: posology of Exjade, and biological monitoring recommendation for Exjade.; Success criteria of the survey will be based on the observed mean correct response rate for each section. ; A threshold of correct response rate of at least 70% or more will be considered as a success for each section of the survey. ; The mean correct response rate (in percentage) for each survey section is calculated taking the average of the proportion of correct responses within each section (total number of correct responses X 100/total number of questions in each section) based on all physicians participating in the survey.